

PIP4K2A (D83C1) Rabbit mAb

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H M R Mk B Pg	Endogenous	50	Rabbit IgG	#P48426	5305

Product Usage Information**Application**

Western Blotting

Dilution

1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

PIP4K2A (D83C1) Rabbit mAb recognizes endogenous levels of total PI 5-P 4-kinase type-2 alpha (PIP4K2A) protein. This antibody does not cross-react with PIP4K2B or PIP4K2C and is not predicted to cross-react with type I PIP5Ks or PIKfyve.

Species predicted to react based on 100% sequence homology

Dog, Horse

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PIP4K2A protein.

Background

Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PtdIns 4-Kinase type II alpha, PIP4K2A), is one of three known members of the type II PIP kinase family, consisting of PIP4K2A, PIP4K2B, and PIP4K2C. Each catalyzes the phosphorylation of phosphatidylinositol 5-monophosphate (PI 5-P) to form phosphatidylinositol 4,5-bisphosphate (PI 4,5-P₂). Originally thought to be a PI 4-P 5-Kinase (1,2), PIP4K2A was subsequently shown to phosphorylate the 4-position of PI 5-P, thus defining a new family of lipid kinases (3). Ubiquitously expressed with highest levels in the brain, mutations in PIP4K2A have been described in patients with Schizophrenia and other neuronal disorders (4-8).

The levels of PI 5-P change significantly in response to physiological and pathological stimuli (5-12), as well as cell transformation with nucleophosmin anaplastic lymphoma tyrosine kinase (13). In contrast, hypoosmotic shock and histamine decrease cellular levels of PI 5-P (14,15). PIP4K2A has been hypothesized to play a role in suppressing mitogen-dependent increases in PI 5-P in response to DNA damage and cellular stress (16-18). PIP4K2A regulates the levels of PI 5-P in the nucleus by converting the PI 5-P to PI 4,5-P₂, thus preventing PI 5-P from interacting with and regulating the ability of ING2 to activate p53 and p53-dependent apoptotic pathways (19). PIP4K2A has been shown to form a heterodimer with PIP4K2B resulting in its recruitment to the nucleus. Interestingly, PIP4K2A is 2000-fold more active than PIP4K2B in this context, suggesting that the two lipid kinases act in tandem, with PIP4K2B acting as the targeting subunit and PIP4K2A the catalytic component (18). PIP4Ks may also play a role in lipid vesicle formation and/or Golgi homeostasis (20).

Background References

- Divecha, N. et al. (1995) *Biochem J* 309 (Pt 3), 715-9.
- Boronenkov, I.V. and Anderson, R.A. (1995) *J Biol Chem* 270, 2881-4.
- Rameh, L.E. et al. (1997) *Nature* 390, 192-6.
- Stopkova, P. et al. (2003) *Am J Med Genet B Neuropsychiatr Genet* 123B, 50-8.
- Schwab, S.G. et al. (2006) *Mol Psychiatry* 11, 837-46.
- Bakker, S.C. et al. (2007) *Genes Brain Behav* 6, 113-9.
- Fedorenko, O. et al. (2008) *Psychopharmacology (Berl)* 199, 47-54.
- Salazar, G. et al. (2009) *J Biol Chem* 284, 1790-802.
- Morris, J.B. et al. (2000) *FEBS Lett* 475, 57-60.
- Sbrissa, D. et al. (2004) *Endocrinology* 145, 4853-65.
- Guittard, G. et al. (2009) *J Immunol* 182, 3974-8.
- Sarkes, D. and Rameh, L.E. (2010) *Biochem J* 428, 375-84.
- Coronas, S. et al. (2008) *Biochem Biophys Res Commun* 372, 351-5.
- Sbrissa, D. et al. (2002) *J Biol Chem* 277, 47276-84.
- Roberts, H.F. et al. (2005) *FEBS Lett* 579, 2868-72.
- Doughman, R.L. et al. (2003) *J Membr Biol* 194, 77-89.
- Wilcox, A. and Hinchliffe, K.A. (2008) *FEBS Lett* 582, 1391-4.
- Bultsma, Y. et al. (2010) *Biochem J* 430, 223-35.

19. Gozani, O. et al. (2003) *Cell* 114, 99-111.
20. De Matteis, M.A. et al. (2005) *Biochim Biophys Acta* 1744, 396-405.
-

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween@ 20 at 4°C with gentle shaking, overnight.
Applications Key	W: Western Blotting
Cross-Reactivity Key	H: Human M: Mouse R: Rat Mk: Monkey B: Bovine Pg: Pig
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	<p>Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.</p> <p>Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.</p>